Japanese Ministry of Health panel approves approval of Novavax COVID-19 vaccine: report

  • Japan’s Health Ministry panel cleared plan for approval Novavax Inc NVAX The COVID-19 vaccine, which is expected to be the fourth such vaccine to be approved in Japan.
  • It will be available for the first and second shots with a three-week interval.
  • The Novavax product is a recombinant protein vaccine that uses parts of the coronavirus protein.
  • Related: Early Data Shows Novavax’s COVID-19 Vaccine Triggers Immune Response to Omicron.
  • The mechanism of the vaccine is different from the three already approved in Japan – Pfizer Inc DFP / BioNTech SE BNTXModerna inc. mrnaand AstraZeneca plc AZN.
  • Novavax vials can be refrigerated at 2-8 degrees Celsius, making them easy to transport and manage.
  • Read also : Novavax’s COVID-19 Reached FDA Clearance.
  • Takeda Pharmaceutical Co Ltd TAKS is responsible for the distribution of the Novavax vaccine in Japan.
  • The Japanese government has entered into a contract with Takeda to supply 150 million doses of vaccines in 2022.
  • Price Action: NVAX shares are down 5.84% at $55.15 when last checked on Monday.
  • Photo by Daniel Schludi on Unsplash

Maria J. Book